reported net income for the second quarter was $num-one million, and diluted earnings per share were $num-two.
and finally, non-gaap net income for the second quarter of year-six was $num-one million or $num-two diluted earnings per share compared to $num-three million or $num-four per share in qtr-two of year-five.
net sales for the second quarter of year-six were $num-one million, which is a num-two% increase on a reported basis versus $num-three million in qtr-two of year-five.
excluding covid-related sales, the non-gaap year-over-year currency-neutral sales growth in the second half is expected to be between num-one% and num-two%.
we are now guiding non-gaap currency-neutral revenue growth to be between num-one% and num-two% for year-six versus our prior guidance of num-three% to num-four%.
this updated outlook assumes the full year covid-related sales to be between $num-one million and $num-two million, of which approximately $num-three million to $num-four million are projected for the second half of year-six.
on a currency-neutral basis, sales increased num-one%.
sales of the clinical diagnostics group in the second quarter were $num-one million compared to $num-two million in qtr-two of year-five, which is a num-three% increase on a reported basis and a num-four% increase on a currency-neutral basis.
these exclusions moved the gross margin for the second quarter of year-six to a non-gaap gross margin of num-one% versus num-two% in qtr-two of year-five.
sales of the life science group in the second quarter of year-six were $num-one million compared to $num-two million in qtr-two of year-five, which is a num-three% increase on a reported basis and a num-four% increase on a currency-neutral basis.
this represents between num-one% and num-two% growth in the second half of year-six over the first half of year-six.
full year adjusted ebitda margin is forecasted to be between num-one% and num-two%.
the non-gaap effective tax rate for the second quarter of year-six was num-one% compared to num-two% for the same period in year-five.
we have also excluded certain items below the operating line, which are the increase in value of the sartorius equity holdings of $num-one billion and the $num-two million loss associated with venture investments.
sg and a expenses for qtr-two of year-six were $num-one million or num-two% of sales compared to $num-three million or num-four% in qtr-two of year-five.
our updated annual non-gaap effective tax rate for year-six is projected to be between num-one% and num-two%.